Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, discusses data supporting the FDA approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals), the first and only therapy ...

Charles C. Wykoff, MD, PhD, Retinal Consultants of Texas, spoke to the current state of research on revakinagene taroretcel ...

for the treatment of Macular Telangiectasia type 2 (MacTel). MacTel is a neurodegenerative disease of the retina in adults that causes progressive and irreversible vision loss, significantly ...

Encelto, the first FDA-approved treatment for MacTel, is implanted intravitreally during a surgery performed by a qualified ophthalmologist. The Food and Drug Administration (FDA) has approved ...

Opens in a new tab or window The FDA approved revakinagene taroretcel (Encelto) as the first treatment for adults with idiopathic macular telangiectasia (MacTel) type 2, Neurotech Pharmaceuticals ...